Five things for pharma marketers to know: Wednesday, June 6, 2018

Share this content:

Athenahealth CEO Jonathan Bush has stepped down, effective immediately, amid allegations he attacked his ex-wife more than a decade ago. The company is searching for a replacement and also considering a sale or merger. Jeff Immelt, executive chairman, is overseeing the transition while CFO Marc Levine takes over day-to-day operations. (CNBC)

Former Celgene CEO Bob Hugin has won the Republican Senate primary in New Jersey. He will run against incumbent Democratic Sen. Bob Menendez in November in what will be a closely watched race. (Politico)

Big Pharma does not intend to campaign against the Trump administration's drug pricing plan. Instead, pharma lobbyists are planning to work with the White House to develop policies that reach a compromise. (Washington Examiner)

Allergan has received a letter from investment firms pressuring the pharma company to make changes to its management. In the letter, Appaloosa and Senator suggested dividing the CEO and chairperson roles and reorganizing divisional management, among other requests. (Credit Suisse)

SSR Health has released data showing that drug prices dropped 5.6% in the first quarter but list prices increased by 6.2%. The company noted that copay accumulators caused the increase in drug prices for drug manufacturers and patients since these adjustments do not count toward deductibles and out-of-pocket maximums. (CNBC)

Share this content:
Scroll down to see the next article